NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Artiva Biotherapeutics, Inc. (ARTV) Stock Analysis

Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARTV

$11.19

+$0.06 (+0.58%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARTV with… →

ARTV Key Statistics

As of Sep 4, 2026
Trading
Open
$11.02
Previous Close
$11.13
Day's Range
10.94–11.34
52-Week Range
2.22–14.53
Volume
168.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.20
Valuation
Market Cap
$547.08M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.23
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$83.87M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.89M
1-Year Return
+259.81%
Dividend and dates
Avg Volume
474.91K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARTV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+160.84%
2025−57.44%
2024 (partial year)−16.00%

As of September 4, 2026.

ARTV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$83.87M—
2024$251.00K−$58.18M−23178.9%
2023$33.49M−$32.77M−97.8%
2022$4.93M−$60.98M−1236.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$89.81M−$83.87M—
2024$251.00K—−$67.28M−$58.18M−23178.9%
2023$33.49M—−$30.67M−$32.77M−97.8%
2022$4.93M—−$59.83M−$60.98M−1236.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARTV Valuation vs Biotechnology Median

Median of 656 stocks
MetricARTVBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Artiva Biotherapeutics, Inc. (ARTV) is capitalised at $547.08M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 115.

ARTV last closed at $11.19 on September 4, 2026. That is +$0.06 (+0.58%) against the previous close. The 52-week range on file runs from $2.22 to $14.53. The latest close sits 404.05% above that 52-week low.

Financial Health

In fiscal 2025, Artiva Biotherapeutics, Inc. reported revenue of $0.00. Against the prior fiscal year total of $251.00K, that is a change of −100.00%. The same year closed with a net loss of $83.87M. The reported profit margin is 0%. Trailing earnings per share are −3.23.

Across the 4 fiscal years on file, revenue moves from $4.93M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +259.81%. The stored price history starts on July 19, 2024, and the total return since then is −6.75%. Beta against the wider market is reported at 2.2. Annualized volatility over the trailing 2 years is 155.99%.

Growth & Income

No dividend is on file for ARTV.

So far in 2026 the price is +160.84%. The record holds one complete calendar year, 2025, which returned −57.44%.

Peer Comparison

Artiva Biotherapeutics, Inc. (ARTV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Artiva Biotherapeutics, Inc. ARTV $547.08M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Artiva Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Visit website →